Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
A video roundup of the week’s top industry news stories.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Anderson will oversee the company’s scientific strategy and pipeline development.
January 27, 2026
By: Patrick Lavery
Content Marketing Editor
Integrated Biosciences has a new Chief Scientific Officer (CSO), naming Daniel J. Anderson, PhD, to the post. Anderson joins from Eikon Therapeutics, and previously worked for Recursion Pharmaceuticals, Cleave Biosciences, and Genentech.
Based in Redwood City, Calif., Integrated Biosciences is a biotechnology company combining the fields of synthetic biology, chemistry, and AI. By doing this, the company discovers small-molecule therapeutics for age-related diseases.
Anderson’s role is to oversee Integrated Biosciences’ scientific strategy and pipeline development. In this way, the company says Anderson’s leadership will help build upon its proprietary platform.
Integrated Biosciences said Anderson has advanced 10 programs into the clinic in his career. In his previous work, he has focused on cutting-edge technology and data science approaches to drug discovery.
“Integrated Biosciences has built a platform that tightly couples precise biological perturbation with high-content measurements and AI-driven learning,” Anderson said. “The exceptional platform has produced a pipeline with real promise for age-related diseases. I’m excited to help accelerate translation from discovery to the clinic and facilitate bringing important new medicines to patients.”
Felix Wong, PhD, Integrated Biosciences co-founder and CEO, applauded the move.
“[Anderson’s] decision to join Integrated Biosciences underscores the strength of our science, platform, and the opportunity ahead,” Wong said. “His track record of building high-growth teams at Eikon Therapeutics and his scientific rigor position him perfectly to help lead.”
Another co-founder, Max Wilson, PhD, will move into the role of Chief Technology Officer. This post will focus on advancing Integrated Biosciences’ core technology platform, including next-generation AI-enabled discovery.
“[Anderson] brings over 20 years of experience in biotechnology and drug discovery,” Wilson said. “I’m excited to focus on scaling our technology platform alongside him.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !